home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

NanoString Technologies

« Back to company
Press Releases

$80 million

Tools & Diagnostics
Research Oncology

NanoString Technologies Announces Pricing of Upsized Offering of $200 Million of Convertible Senior Notes »

NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock »

NanoString Announces $100 Million Term Loan Facility with CRG »

NanoString Technologies Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock »

Humana Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay »

Cigna Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay »

Aetna Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay »

NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test »

NanoString Technologies Expands 3D Biology Portfolio With the Commercial Launch of Seven New nCounter PanCancer Profiles to Deeply Probe Cancer Biology »

NanoString Technologies Expands Immuno-Oncology Portfolio With Commercial Launch of Innovative nCounter RNA:Protein PanCancer Immune Profiling Panel »

ESMO Clinical Practice Guidelines for Breast Cancer Recommend the Use of Prosigna/PAM50 Assay for Determining Potential Benefit From Chemotherapy »

NanoString Technologies Receives Favorable Final Local Coverage Determination by Palmetto GBA for Its Prosigna Breast Cancer Assay »

NCCN Clinical Practice Guidelines for Breast Cancer Acknowledge Prosigna/PAM50 as Clinically Validated for Prediction of Prognosis »

NanoString Technologies Launches New nCounter SPRINT(TM) Profiler Designed to Meet Needs of the Individual Researcher »

Expanded nCounter® Instrument Product Line Expected to Reach Deeper Into Cancer Research Market  


Seattle, July 15, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of the nCounter Analysis System product portfolio with the launch of the nCounter SPRINT Profiler. Sales of the new system have already begun, with the first two SPRINT systems being purchased in late June by a major academic research center.


The new nCounter SPRINT represents a major step forward in making nCounter technology more broadly accessible to researchers. It provides the same high-precision nCounter chemistry as the company's previous systems, but with a smaller footprint, and sample throughput and cost attuned to the needs of individual researchers. The new system integrates sample prep and analysis into a single instrument, minimizing manual steps, while further streamlining the overall workflow. The system throughput has been designed to accelerate sample-to-data for individualized experiments, on a unit sized to fit on a laboratory bench top.


Also announced today is the launch of the nCounter MAX system, an update to NanoString's previous research use only version of the nCounter Analysis system, designed to better address the needs of the research core laboratory. The nCounter MAX provides enhanced security, controlled access, automated data transfer and higher sample throughput, which can be doubled when combined with a second Prep Station.


Together with the nCounter Dx FLEX system, this brings the expanded and segmented instrument line to three systems. The nCounter Dx FLEX system is a highly flexible system designed for clinical laboratories. The FLEX system is 510(k) cleared by the FDA for diagnostic use with the company's Prosigna® Breast Cancer Assay. It can also be used in research mode to translate research cancer signatures into clinical applications. The FLEX system has been updated to benefit from enhanced security features and the generation of audit logs in its research mode.


"The new nCounter SPRINT, combined with our suite of PanCancer panels and custom CodeSet content, provides the cancer researcher with a complete solution for translational research," said Barney Saunders, Ph.D., Senior Vice President of Sales and Marketing at NanoString Technologies. "The expanded line of nCounter systems now spans from individual researchers to large scale enterprises running major clinical trials and diagnostic tests."


All three nCounter Systems run consumables based on NanoString's digital molecular barcoding technology. All systems are capable of using a wide variety of sample types such as purified total RNA, raw cell or blood lysates and formalin-fixed-paraffin-embedded extracts, and are compatible with the company's new RNA:Protein profiling assay currently available to select customers through a product access program. The data from all systems can be analyzed using the nSolver™ Analysis Software.


About NanoString Technologies, Inc.


NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 700 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has also been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.


For more information, please visit www.nanostring.com.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential for the nCounter Sprint Profiler to expand the market opportunity for the company's products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with keeping pace with rapidly changing technology and customer requirements; risks regarding the company's ability to successfully introduce new products; risks that new market opportunities may not develop as quickly as expected; risks associated with competition in marketing and selling products; risks of increased regulatory requirements; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.


The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, nCounter SPRINT, nSolver and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.


CONTACT: Investor Contact:


         Leigh Salvo of Westwicke Partners





Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab) »

St. Gallen International Breast Cancer Guidelines Recognize Power of Prosigna/PAM50 to Inform Treatment Decisions and Spare Low Risk Breast Cancer Patients Unnecessary Chemotherapy »

NanoString Technologies Empowers Cancer Researchers With Three Innovative New Products for the nCounter Analysis System »

NanoString Technologies' Prosigna Breast Cancer Assay Included in German Breast Cancer Treatment Guidelines »

NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis »

NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay »